Man­u­fac­tur­ing roundup: mR­NA man­u­fac­tur­er nets $300M+ in­vest­ment to scale re­search; Cy­ti­va ac­quires Michi­gan fa­cil­i­ty

As mR­NA tech has been made more pop­u­lar by the Covid-19 pan­dem­ic, in­vestor cash is mak­ing its way to man­u­fac­tur­ers and re­searchers.

In their lat­est move, Irish biotech Nor­max Bio­med has net­ted a €300 Mil­lion, or $305 mil­lion, in­vest­ment from pri­vate firm GEM Glob­al Yield.

The deal will see GEM pro­vide Nor­max with a share sub­scrip­tion fa­cil­i­ty of up to €50 Mil­lion for a 36-month term fol­low­ing the pub­lic list­ing of the Nor­max com­mon stock.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.